AstraZeneca has fired another shot in its bladder cancer competition with Merck’s Keytruda, with the FDA clearing its PD-L1 inhibitor Imfinzi, used alongside standard of care, to become the first immunotherapy combination regimen for patients with high-risk non-muscle-invasive bladder cancer.
read moreA group of over 20 global pharma leaders met with Japan’s Prime Minister Sanae Takaichi to address Japan’s declining share of biopharma R&D. More: Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge Source: fierce
read moreThe top pharmacy benefit manager in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, allowing a significant number of patients to gain access to the drugs through their existing insurance. More: CVS restores coverage of
read morePharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization as it seeks to broaden the label of its rare blood cancer drug Besremi to a much wider market. More: PharmaEssentia taps Incyte alum Eric Vogel as it
read moreKaléo has launched the “AUVI-Q Speaks Up” campaign to share patients’, caregivers’ and healthcare providers’ stories about life with severe allergies. More: Kaléo speaks up on allergy awareness to amplify patient stories Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals